Weekly Scan · 1–7 June 2026 · No material signal change
No development this week changed the IOL access, pricing, or payment position. The renewal scheme and the July payment-grouping revision remain the near-term watch points.
Across the week of 1–7 June 2026, no development changed the market-access, pricing, or payment position for intraocular lenses in China. The position set out in recent OphthalLogix analysis stands.
This week’s scan covered the national medical insurance, drug regulation, and high-value device procurement channels, the medical-insurance bureaus of fourteen priority provinces and municipalities, and the disclosures of listed ophthalmic companies. The developments recorded were either continuations of known annual processes or supply-side product news that does not, on its own, change procurement access. None of them shifts what a market-access or investment team should do this week.
Three items remain under active watch:
· The next national payment-grouping revision. A revised version of the DRG/DIP grouping framework is expected in July, with thirty clinical specialities already through validation. Whether the revised cataract and ophthalmology groupings change hospital economics is the development to watch; the operating version takes effect from January 2027, so the preparation window is open now.
· The second-round procurement renewal for intraocular lenses. The first-wave provincial agreements lapsed at the end of May; Beijing follows on 28 June and Hunan on 30 June. No renewal scheme has yet been published. The absence of a national or first-wave transitional notice past Beijing’s expiry would carry the question into a second wave.
· The widening field of domestically approved premium lenses. More domestic trifocal and extended-depth-of-focus products have cleared approval over the past two years. Approval is not procurement access, and how these products enter — or stay outside — the next procurement round is the question that will decide whether domestic premium lenses compete on price or sit alongside imports.
For teams tracking China’s IOL market, the near-term decision points are the renewal scheme and the July grouping revision, not this week’s flow. OphthalLogix publishes when a development changes the position, not to fill a calendar.
This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.